<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715894</url>
  </required_header>
  <id_info>
    <org_study_id>Conduct prospective</org_study_id>
    <nct_id>NCT03715894</nct_id>
  </id_info>
  <brief_title>Prospective Arm of Conduct - Edwards SAPIEN3 PPI Registry</brief_title>
  <acronym>Conduct-pro</acronym>
  <official_title>Edwards SAPIEN 3 PPI Registry - A Retrospective Survey and Prospective Identification of Procedure Related Variables Associated With Permanent Pacemaker Implantation in Patients Receiving an Edwards SAPIEN 3 Valve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are procedure related risk factors for permanent pacemaker implantation (PPI) that can&#xD;
      be identified and assessed in a prospective cohort of 300 patients at high risk for PPI&#xD;
&#xD;
      Prospective, multicenter, European registry in patients at high risk for PPI undergoing TAVI&#xD;
      with the Edwards SAPIEN 3 valve. Additional assessment of calcification using a CT data core&#xD;
      lab. Statistical analysis of the dataset obtained with respect to the objectives of the&#xD;
      registry.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Permanent pacemaker implantation is a widely recognized clinical event associated with TAVI&#xD;
      becoming evident within a few days after the procedure.&#xD;
&#xD;
      While a number of registries have documented the rates of PPI with different valves, much&#xD;
      less evidence has been provided for&#xD;
&#xD;
        1. patient based characteristics (e.g. RBBB etc.) affecting the likelihood of PPI and for&#xD;
&#xD;
        2. procedural variables (e.g. implantation hieght, valve size etc.) that should be&#xD;
           considered to perform as safe and minimal invasive procedure as possible.&#xD;
&#xD;
      Prior Research To date there are 8 published reports on pacemaker rates and predictors&#xD;
      associated with the use of the Edwards SAPIEN 3 THV.&#xD;
&#xD;
      These studies suggest that the need for pacemaker implantation in single centers ranges&#xD;
      between 14.4 and 20.4% based on patient numbers between 131 and 335 patients.&#xD;
&#xD;
      These analyses resulted in the identification of pre-existing conduction disturbance, aortic&#xD;
      valve calcification, heavily calcified LVOT, RBBB, persistent complete heart blocks,&#xD;
      prolonged QRS duration or short membranous septum as patient related factors associated with&#xD;
      PPI during Edwards SAPIEN 3 THV TAVI. Similarly, procedural variables such as implantation&#xD;
      height /oversizing as procedure related variables are associated with PPI after TAVI.&#xD;
&#xD;
      The literature regarding procedure related variables associated with permanent pacemaker&#xD;
      implantation in patients receiving an Edwards SAPIEN 3 valve shows multivariable analyses&#xD;
      with slightly different views to the requested procedural variables.&#xD;
&#xD;
      Tarantini et al. suggest a higher valve implantation (ventricular ratio &gt;60/40 at qualitative&#xD;
      assessment or depth &lt;8mm at qualitative assessment). A similar outcome was reported by De&#xD;
      Torres-Alba et al.. Due to the longer stent of the SAPIEN 3 they suggest an even higher&#xD;
      implantation, intending a shorter extension of the stent into the LVOT by increasing the&#xD;
      percentage of the stent in the aorta to &gt;70%. Schwerg et al. compare the PPI rate in &quot;low&#xD;
      implantation&quot; with &quot;high implantation&quot; independently from the patients pre-existing&#xD;
      conduction disturbances, and suggest to minimize the risk of PPI by choosing a higher&#xD;
      implantation technique with the central marker 2 mm or more over the annular plane.&#xD;
&#xD;
      Furthermore Mauri et al. encourage to choose a implantation height of &lt;25.5% (Implantation&#xD;
      height was expressed as the percentage of the ventricular part of the stent frame in relation&#xD;
      to the overall stent frame length).&#xD;
&#xD;
      Another procedural factor is found to be aortic annulus oversizing ratios which are known to&#xD;
      prevent paravalvular leakage. Leber et al. show the rate of post-procedural permanent&#xD;
      pacemakers tended to be lower in patients with &lt;15% oversizing compared to those with &gt;25%&#xD;
      oversizing for Edwards Sapien XT. Using SAPIEN 3 valves Husser et al. show a higher PPI rate&#xD;
      in patients with out of range oversizing.&#xD;
&#xD;
      Gonska et al. conclude that neither implantation height nor oversizing has an effect on PPI&#xD;
      rate.&#xD;
&#xD;
      On the other hand the need for pre-dilatation by balloon valvuloplasty and post-implant&#xD;
      dilatation have not been identified as potential contributing factors for PPI as it is&#xD;
      believed the impact of the dilatation on the conduction tissue is transient and short lived.&#xD;
&#xD;
      Nevertheless, pre- and post-dilatation should be further considered and analysed.&#xD;
&#xD;
      Hypothetically, also the following procedural parameters, which have not been investigated in&#xD;
      detail so far, could be risks for PPIs: Stiff guidewire use or a no touch policy and should&#xD;
      be considered in this research.&#xD;
&#xD;
      Limitations of prior research Current evidence though is limited by patient numbers versus&#xD;
      event rates (with a max. of 62 PPI considered in any of the available datasets) resulting in&#xD;
      a limited power in multivariable analyses, the single center design of these ventures, the&#xD;
      lack of a consistent definition of variables potentially associated with PPI and the&#xD;
      unexplained differences in the number and type of variables identified.&#xD;
&#xD;
      Aims This registry aims to assess procedural variables and to verify risk factors in a&#xD;
      prospective multicenter registry.&#xD;
&#xD;
      To identify predictors of PPI patients with a high risk for PPI will be preferably included&#xD;
      to increase the power compared to pre-existing database analyses from single centres. The&#xD;
      target is to identify general procedural predictors and to verify risk factors of PPI post&#xD;
      TAVI with the Edwards SAPIEN 3 valve which when identified and avoided will reduce the need&#xD;
      of PPI in the future.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of permanent pacemaker implantation after TAVI in high risk patients</measure>
    <time_frame>1 year</time_frame>
    <description>Need for permanent pacemaker implantation after TAVI in high risk patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation depth</measure>
    <time_frame>up to 30 days after intervention</time_frame>
    <description>Measurement in peri-interventional aortic angiograms. Mean implantation depth (% ventricular part of the stent frame)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve sizing</measure>
    <time_frame>up to 30 days after intervention</time_frame>
    <description>Measurement of aorta in pre-operative contrast multislice computed tomographic Images, compared to the implanted valve sizing. Percentage of oversizing will be calculated using the formula (nominal prosthesis area/multislice computed tomographic area - 1) x 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dilatation</measure>
    <time_frame>1 year</time_frame>
    <description>Ratio in patients, who get a dilatation before or at intervention as well as thereafter (discharge, FU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expiration data</measure>
    <time_frame>2 years</time_frame>
    <description>cause of death</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>AV Block</condition>
  <condition>Bundle-Branch Block</condition>
  <arm_group>
    <arm_group_label>Patients with aortic stenosis</arm_group_label>
    <description>Patients receiving Edwards SAPIEN 3 aortic transcatheter valve Implantation, who are with a high risk for PPI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transcatheter valve implantation</intervention_name>
    <description>aortic transcatheter valve implantation using Edwards SAPIEN 3 valve</description>
    <arm_group_label>Patients with aortic stenosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing transfemoral transcatheter valve implantation with the SAPIEN 3 valve&#xD;
        with at least one identified risk factor for PPI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing transfemoral SAPIEN 3 implantation because of aortic stenosis,&#xD;
&#xD;
          -  at least 1 of the identified risk factors from the retrospective part to ensure a&#xD;
             minimum risk of 33% for PPI (presumed: pre-existing conduction disturbance, aortic&#xD;
             valve calcification, heavily calcified LVOT, RBBB, persistent complete heart blocks,&#xD;
             QRS duration or short membranous septum,to be confirmed);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  exclusion of patients with prior pacemaker,&#xD;
&#xD;
          -  with indications for pacemaker implantation prior to TAVI&#xD;
&#xD;
          -  valve in valve implantation or&#xD;
&#xD;
          -  without informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Geisler, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Clinic Tübingen, Tübingen, Germany - Department of Internal Medicine III</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maren Froehlich</last_name>
    <phone>+49 441 92517813</phone>
    <email>maren.froehlich@ippmed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Bramlage, Prof. Dr.</last_name>
    <phone>+49 3379 3147890</phone>
    <email>peter.bramlage@ippmed.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Clinic Tübingen, Department of Internal Medicine III</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Geisler, Prof</last_name>
      <phone>+49 7071 2982712</phone>
      <email>tobias.geisler@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic Ulm, Department of Internal Medicine II</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochen Wöhrle, Prof.</last_name>
      <phone>+49 731 50045047</phone>
      <email>jochen.woehrle@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum</name>
      <address>
        <city>Bad Oeynhausen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Rudolph, Prof.</last_name>
      <email>tk.rudolph@me.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Baan, MD PhD</last_name>
      <phone>+ 31 6 23426758</phone>
      <email>j.baan@amc.uva.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept of Cardiology, Linköping University Hospital,</name>
      <address>
        <city>Linköping,</city>
        <zip>58183</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niels Erik Nielsen, Dr.</last_name>
      <phone>+46 10 1032110</phone>
      <email>niels.erik.nielsen@regionostergotland.se</email>
    </contact>
    <contact_backup>
      <last_name>Jacek Baranowski, Dr.</last_name>
      <email>jacek.baranowski@regionostergotland.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Bob-Manuel T, Nanda A, Latham S, Pour-Ghaz I, Skelton WP 4th, Khouzam RN. Permanent pacemaker insertion in patients with conduction abnormalities post transcatheter aortic valve replacement: a review and proposed guidelines. Ann Transl Med. 2018 Jan;6(1):11. doi: 10.21037/atm.2017.10.21. Review.</citation>
    <PMID>29404357</PMID>
  </reference>
  <reference>
    <citation>De Torres-Alba F, Kaleschke G, Diller GP, Vormbrock J, Orwat S, Radke R, Reinke F, Fischer D, Reinecke H, Baumgartner H. Changes in the Pacemaker Rate After Transition From Edwards SAPIEN XT to SAPIEN 3 Transcatheter Aortic Valve Implantation: The Critical Role of Valve Implantation Height. JACC Cardiovasc Interv. 2016 Apr 25;9(8):805-813. doi: 10.1016/j.jcin.2015.12.023. Epub 2016 Mar 23.</citation>
    <PMID>27017367</PMID>
  </reference>
  <reference>
    <citation>Maeno Y, Abramowitz Y, Kawamori H, Kazuno Y, Kubo S, Takahashi N, Mangat G, Okuyama K, Kashif M, Chakravarty T, Nakamura M, Cheng W, Friedman J, Berman D, Makkar RR, Jilaihawi H. A Highly Predictive Risk Model for Pacemaker Implantation After TAVR. JACC Cardiovasc Imaging. 2017 Oct;10(10 Pt A):1139-1147. doi: 10.1016/j.jcmg.2016.11.020. Epub 2017 Apr 12.</citation>
    <PMID>28412434</PMID>
  </reference>
  <reference>
    <citation>Tarantini G, Mojoli M, Purita P, Napodano M, D'Onofrio A, Frigo A, Covolo E, Facchin M, Isabella G, Gerosa G, Iliceto S. Unravelling the (arte)fact of increased pacemaker rate with the Edwards SAPIEN 3 valve. EuroIntervention. 2015 Jul;11(3):343-50. doi: 10.4244/EIJY14M11_06.</citation>
    <PMID>25405801</PMID>
  </reference>
  <reference>
    <citation>Mauri V, Reimann A, Stern D, Scherner M, Kuhn E, Rudolph V, Rosenkranz S, Eghbalzadeh K, Friedrichs K, Wahlers T, Baldus S, Madershahian N, Rudolph TK. Predictors of Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement With the SAPIEN 3. JACC Cardiovasc Interv. 2016 Nov 14;9(21):2200-2209. doi: 10.1016/j.jcin.2016.08.034.</citation>
    <PMID>27832845</PMID>
  </reference>
  <reference>
    <citation>Gonska B, Seeger J, Keßler M, von Keil A, Rottbauer W, Wöhrle J. Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve. Clin Res Cardiol. 2017 Aug;106(8):590-597. doi: 10.1007/s00392-017-1093-2. Epub 2017 Mar 10.</citation>
    <PMID>28283746</PMID>
  </reference>
  <reference>
    <citation>Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, Kasel AM, Kastrati A, Schunkert H, Hengstenberg C. Predictors of Permanent Pacemaker Implantations and New-Onset Conduction Abnormalities With the SAPIEN 3 Balloon-Expandable Transcatheter Heart Valve. JACC Cardiovasc Interv. 2016 Feb 8;9(3):244-254. doi: 10.1016/j.jcin.2015.09.036.</citation>
    <PMID>26847116</PMID>
  </reference>
  <reference>
    <citation>Schwerg M, Fulde F, Dreger H, Poller WC, Stangl K, Laule M. Optimized Implantation Height of the Edwards SAPIEN 3 Valve to Minimize Pacemaker Implantation After TAVI. J Interv Cardiol. 2016 Aug;29(4):370-4. doi: 10.1111/joic.12302. Epub 2016 May 31.</citation>
    <PMID>27240558</PMID>
  </reference>
  <reference>
    <citation>Fujita B, Kütting M, Seiffert M, Scholtz S, Egron S, Prashovikj E, Börgermann J, Schäfer T, Scholtz W, Preuss R, Gummert J, Steinseifer U, Ensminger SM. Calcium distribution patterns of the aortic valve as a risk factor for the need of permanent pacemaker implantation after transcatheter aortic valve implantation. Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1385-1393. Epub 2016 Jan 12.</citation>
    <PMID>26758411</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter aortic valve implantation</keyword>
  <keyword>Pacemaker</keyword>
  <keyword>Aortic valve calcification</keyword>
  <keyword>PPI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Bundle-Branch Block</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no IPD will be made available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

